The Michael J. Fox Foundation (MJFF) has announced a partnership with H1, a New York-based healthcare data company, to streamline its search for physicians actively treating patients with Parkinson’s disease and gather insights on patient populations and treatment approaches.
MJFF will use H1’s Trial Landscape, an AI-powered platform that uses performance data to gain insights into researchers and clinical trial sites, to connect with healthcare providers and advance its education and research initiatives.
The foundation will also gain insight into underrepresented patient populations and the challenges they face in order to develop strategies to effectively support them.
“Our efforts to improve treatments and cures for Parkinson’s disease rely on partnerships. People with the disease or risk factors, their loved ones, teams of scientists and healthcare providers all play a role in the development and testing of new strategies to prevent progression and relieve symptoms. We have engaged with H1 to help us expand our network of partners and thereby accelerate breakthroughs,” said Maggie McGuire Kuhl, vice-president Chair of Research Engagement at the Michael J. Fox Foundation. MobiHealthNews in an email.
THE GREAT TREND
Nearly one million people in the United States living with Parkinson’s disease. However, representation of people within marginalized communities in clinical trials has been weak.
In April, a study was published in The Lancetsponsored by the MJFFwhich showed a significant breakthrough in research on Parkinson’s disease: the discovery of a biomarker that allows the detection of the disease in individuals before the onset of the cardinal symptoms of movement, via a cerebrospinal fluid test, with high diagnostic accuracy.
In a report After the study was published, the foundation said the results suggest that people with Parkinson’s can expect improved care and treatment, and those newly diagnosed may never experience any symptoms. full symptoms.
Another company working to advance Parkinson’s disease research is based in California. Rune Laboratoriesa precision neurology software and data platform company.
In March, Rune announced a partnership with BlueRock Therapeutics, a clinical-stage biopharmaceutical company that is a subsidiary of Bayer AG, to help study Parkinson’s disease. BlueRock will use Rune Labs’ clinical development platform, StriveStudy, for recruiting clinical trials, generating real-world evidence, and monitoring patient compliance in a study.